Vycor Medical, Inc (VYCO) Fair Value & Analysis
Healthcare · US · Market cap $2.2M
Vycor Medical, Inc
VYCO · US
Fair value as of: Jul 31, 2026
From 5 valuation models · updated 10 days ago
Fair value updated Jul 31, 2026, revised from $0.0290 to $0.0283 (−2.5%) since Jun 26, 2026. Share price +9.5% over the past month.
Below-average quality, and screening another 59% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0352). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
60‑month range $0.0500 – $0.2800 · fair‑value band $0.0283 – $0.0352 · the $0.0690 price screens above the $0.0283 fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
Vycor Medical, Inc (VYCO) currently trades at $0.0690, while our model-based Fair Value estimate is $0.0283, implying the stock looks roughly 59.0% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Vycor Medical, Inc generated revenue of $1.9M at a net margin of -0.7%. Revenue grew 5.1% year over year. Fundamentals as of Jul 31, 2026
Our scenario range runs from $0.0283 (bear case) to $0.0352 (bull case); at $0.0690, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high and 35% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -59%, VYCO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 5 models by family
Widest divergence: Multiples ($0.0200) versus Earnings-Based ($0.0100). Highest evidence: ROIC Compounder (72).
Notify me when VYCO reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company operates through two segments: Vycor Medical and NovaVision.
Full company description
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company operates through two segments: Vycor Medical and NovaVision. Its Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement with a German-based partner. It primarily serves hospitals and medical professionals. The company was incorporated in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. operates as a subsidiary of Fountainhead Capital Management Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vycor Medical, Inc reported revenue of $1.9M in FY2025 versus $1.4M in FY2021, a compound +7.5%/yr. Reported net income was −$72.4K in FY2025.
VYCO screens 59% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Vycor Medical, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vycor Medical, Inc (VYCO) overvalued or undervalued?
What is the fair value of VYCO?
What is the quality score of VYCO?
What is the revenue of Vycor Medical, Inc (VYCO)?
What is the net profit margin of VYCO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Vycor Medical, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.